{
  "id": 1215562,
  "title": "Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?",
  "url": "https://urgent.news/2026/08/14/can-keros-therapeutics-kros-s-20m-takeda-pharmaceutical-company",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T23:37:12.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/keros-therapeutics-kros-20m-takeda-233712991.html"
  },
  "original_language": "en",
  "account": "On July 30, Keros Therapeutics (KROS) reached a $20 million development milestone payment from partner Takeda Pharmaceutical Company Limited (TAK) after the first patient was dosed in the Phase 3 ELRiSE MDS clinical trial. This payout was part of their January 2025 global licensing agreement, which also granted Keros a $200 million upfront payment and potential future milestones totaling over $1.1 billion in cash and royalties. Keros plans to distribute 25% of the net cash proceeds from this milestone to its shareholders.\n\nComparing Keros Therapeutics' Q2 2026 results against Takeda's Q1 FY2026 performance, Keros reported $0 in total revenue and a net loss of $28.7 million ($1.45 per share), while Takeda reported revenue of JPY 1.22 trillion (~$7.5 billion) and a core EPS of JPY 154 billion. However, Keros' financial situation is bolstered by $257.6 million in cash and equivalents, providing a clean runway through the first half of 2028.\n\nTakeda's financial strength lies in its massive commercial scale, core EPS, and high-margin portfolio. However, Keros Therapeutics is executing well for a clinical-stage firm by leveraging Takeda's resources to offset R&D costs, maintain a zero debt burden, and return capital to shareholders. The primary upside for Keros centers on successful Phase 3 trials of its lead candidate elritercept, which could unlock over $1.1 billion in future milestones and high-margin royalties. The main risk for Keros is its reliance on a single clinical candidate and its complete dependence on Takeda for commercial execution outside China.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}